LLLang Li

Lang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lang Li has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Qiang Su

    Department of Cardiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, No. 6 Shuangyong Rd, Nanning 530021, Guangxi, P.R. China

    22 shared publications
  • You Zhou

    9 shared publications
  • Tao Liu

    8 shared publications
  • Yangchun Liu

    Department of Cardiology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

    7 shared publications
  • Ziliang Ye

    Department of Cardiology, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China

    7 shared publications
  • Xiantao Wang

    Guangxi Med Univ, Dept Cardiol, Affiliated Hosp 1, 21 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China

    6 shared publications

Latest Publications

  • Open Access

    Alprostadil Injection Attenuates Coronary Microembolization-Induced Myocardial Injury Through GSK-3β/Nrf2/HO-1 Signaling-Mediated Apoptosis Inhibition

    by Zhenbai Qin, Binghui Kong, Jing Zheng, Xiantao Wang, Lang Li

    Objective: Coronary microembolization (CME) results in progressive contractile dysfunction associated with cardiomyocyte apoptosis. Alprostadil injection improves microcirculation, which is effective in treating various cardiovascular disorders. However, the therapeutic effects of alprostadil in CME-induced myocardia injury remain unknown. Therefore, we evaluated the effects of alprostadil injection on cardiac protection in a rat model of CME and explored the underlying mechanisms. Methods: A rat model of CME was established by injecting polyethylene microspheres into the left ventricle. After injection of microspheres, rats in the alprostadil group received alprostadil via tail vein within 2 minutes. Cardiac function, histological alterations in myocardium, serum c-troponin I (cTnI) levels, myocardium adenosine triphosphate (ATP) concentrations, the activity of superoxide dismutase (SOD) and malondialdehyde (MDA) content in myocardium, and myocardial apoptosis-related proteins were detected 12 hours after CME modeling. Results: Compared with the Sham group, ATP concentrations, SOD activity in the myocardium, and cardiac function were significantly decreased in a rat model of CME. In addition, serum cTnI levels, MDA content, expression levels of pro-apoptotic proteins, and the number of TUNEL-positive nuclei were remarkably higher in CME group than those in the Sham group. However, alprostadil treatment notably reduced serum cTnI levels and expression levels of pro-apoptotic proteins, while noticeably improved cardiac function, and accelerated SOD activity in the myocardium following CME. Additionally, it was unveiled that the protective effects of alprostadil injection inhibit CME-induced myocardial apoptosis in the myocardium potentially through regulation of the GSK-3β/Nrf2/HO-1 signaling pathway. Conclusion: Alprostadil injection seems to significantly suppress oxidative stress, alleviate myocardial apoptosis in the myocardium, and improve cardiac systolic and diastolic functions following CME by regulating the GSK-3β/Nrf2/HO-1 signaling pathway.


  • Serum Levels of Cystatin C, N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP), and Cardiac Function in Patients with Unstable Angina Pectoris

    by Manyun Long, Lang Li

    Background: This study aimed to investigate the association between serum levels of cystatin C, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac function in patients with unstable angina pectoris (UAP). Material/Methods: A cross-sectional observational study was conducted at a single center and recruited 300 patients (214 men and 86 women), who were diagnosed with UAP between June 2018 to December 2018. The patients had serum levels of NT-ProBNP measured and were divided into four groups according to the serum levels of cystatin C: Q1, 0.49-0.83 mg/L; Q2, 0.84-1.04 mg/L; Q3, 1.05-1.38 mg/L; Q4, 1.39-4.21 mg/L. Cardiac function was graded according to the New York Heart Association (NYHA) class I to IV criteria. Results: In the 300 patients with UAP, there were significant differences in cardiac function and NT-ProBNP levels between the four study groups (Q1 to Q4) (p<0.05). Univariate analysis showed that body weight, heart rate, treatment with aspirin, ticagrelor, angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker (ACE/ARB), diuretic use, uric acid level, and serum cystatin C levels were significantly associated with increased levels of NT-ProBNP. After adjusting for confounding factors screened in univariate analysis, multivariate regression analysis showed that increased serum cystatin C levels were significantly associated with increased levels of NT-ProBNP. Conclusions: Increased serum levels of cystatin C were associated with poor cardiac function and increased levels of NT-ProBNP in patients with UAP.

  • Open Access

    miR‐30e‐3p Promotes Cardiomyocyte Autophagy and Inhibits Apoptosis via Regulating Egr‐1 during Ischemia/Hypoxia

    by Bo Su, Xiantao Wang, Yuhan Sun, Manyun Long, Jing Zheng, Wenhao Wu, Lang Li

    Background. Microvascular obstruction (MVO) can result in coronary microcirculation embolism and myocardial microinfarction. Myocardial injury induced by MVO is characterized by continuous ischemia and hypoxia of cardiomyocytes. Autophagy and apoptosis are closely associated with various cardiovascular diseases. Based on our previous study, we observed a decrease in miR‐30e‐3p expression and an increase in Egr‐1 expression in a rat coronary microembolization model. However, the specific function of miR‐30e‐3p in regulating autophagy and apoptosis in an ischemia/hypoxia (IH) environment remains to be deciphered. We exposed cardiomyocytes to an IH environment and then determined whether miR‐30e‐3p was involved in promoting cardiomyocyte autophagy and inhibiting apoptosis by regulating Egr‐1. Methods. Cardiomyocytes were isolated from rats for our in vitro study. miR‐30e‐3p was either overexpressed or inhibited by transfection with lentiviral vectors into cardiomyocytes. 3‐Methyladenine (3‐MA) was used to inhibit autophagy. RT‐qPCR and western blotting were used to determine the expression levels of miR‐30e‐3p, Egr‐1, and proteins related to the autophagy and apoptosis process. Autophagic vacuoles and autophagic flux were evaluated using transmission electron microscopy (TEM) and confocal microscopy, respectively. Cardiomyocyte viability was evaluated using the MTS assay. Cell injury was assessed by lactate dehydrogenase (LDH) leakage, and apoptosis was determined by flow cytometry. Results. Both miR‐30e‐3p expression and autophagy were significantly inhibited, and apoptosis was increased in cardiomyocytes after 9 hours of IH exposure. Overexpression of miR‐30e‐3p increased autophagy and inhibited apoptosis, as well as suppressed Egr‐1 expression and decreased cell injury. In addition, inhibition of miR‐30e‐3p reduced autophagy and increased apoptosis and cell injury. Conclusions. miR‐30e‐3p may be involved in promoting cardiomyocyte autophagy and inhibiting apoptosis by indirectly regulating Egr‐1 expression in an IH environment.


  • Ischemia/hypoxia inhibits cardiomyocyte autophagy and promotes apoptosis via the Egr-1/Bim/Beclin-1 pathway

    by Bo Su, Xian-Tao Wang, Yu-Han Sun, Man-Yun Long, Jing Zheng, Wen-Hao Wu, Lang Li

    Background Myocardial injury caused by microvascular obstruction (MVO) is characterized by persistent ischemia/hypoxia (IH) of cardiomyocytes after microembolization. Autophagy and Egr-1 were closely associated with various cardiovascular diseases, including MVO. Bim and Beclin-1 are the important genes for autophagy and apoptosis. We aimed to explore whether the Egr-1/Bim/Beclin-1 pathway is involved in regulating autophagy and apoptosis in IH-exposed cardiomyocytes. Methods Neonatal rat cardiomyocytes exposed to the IH environment in vitro were transfected with lentivirus expressing Egr-1 or Egr-1 shRNA, or further treated with 3-methyladenine (3-MA). The expressions of autophagy and apoptosis-associated genes were evaluated using RT-qPCR and Western blots assays. Autophagic vacuoles and autophagic flux were detected by transmission electron microscopy (TEM) and confocal microscope, respectively. Cell injury was assessed by lactate dehydrogenase (LDH) leakage, and apoptosis was determined by flow cytometry. Results IH exposure elevated Egr-1 and Bim expressions, and decreased Beclin-1 expression in rat cardiomyocytes. Egr-1 overexpression in IH-exposed cardiomyocytes significantly up-regulated the levels of Egr-1 and Bim, and down-regulated the level of Beclin-1. Egr-1 knockdown resulted in down-regulated expressions of Egr-1 and Bim, as well as up-regulated expression of Beclin-1. In addition, Egr-1 knockdown induced autophagy was suppressed by 3-MA treatments. TEM and autophagic flux experiments also confirmed that Egr-1 inhibited autophagy progression in IH-exposed cardiomyocytes. Egr-1 suppression protected cardiomyocytes from IH-induced injury, as evidenced by the positive correlations between Egr-1 expression and LDH leakage or apoptosis index in IH-exposed cardiomyocytes. Conclusions IH-induced cardiomyocyte autophagy and apoptosis are regulated by the Egr-1/Bim/Beclin-1 pathway, which is a potential target for treating cardiomyocyte injury caused by MVO in the IH environment.


  • microRNA‐26a‐5p affects myocardial injury induced by coronary microembolization by modulating HMGA1

    by Binghui Kong, Zhenbai Qin, Ziliang Ye, Xuefei Yang, Lang Li, Qiang Su

    Coronary microembolization (CME) occurs when atherosclerotic plaque debris is detached during the treatment of acute coronary syndrome with Percutaneous Coronary Intervention (PCI). The complications of distal microvascular embolism, including local myocardial inflammation, are the main causes of myocardial damage and are a strong predictor of poor long‐term prognosis and major cardiac adverse events. microRNAs (miRNAs) are involved in the pathophysiological processes of cardiovascular inflammatory diseases. Dysregulation of microRNA (miR)‐26a‐5p, in particular, is associated with a variety of cardiovascular diseases. However, the role of miR‐26a‐5p in CME‐induced myocardial injury is unclear. In this study, we developed an animal model of CME by injecting microembolic balls into the left ventricle of rats and found that miR‐26a‐5p expression decreased in myocardial tissue in response. Using a miR‐26a‐5p mimic, echocardiography, hematoxylin‐eosin staining, and Western blot analysis we found that the diminished cardiac function and myocardial inflammation induced by CME is alleviated by miR‐26a‐5p overexpression. Furthermore, our results show that inhibitors of miR‐26a‐5p have the opposite effect. In addition, in vitro experiments using real‐time PCR, Western blot analysis, and a dual luciferase reporter gene show that HMGA1 is a target gene of miR‐26a‐5p. Thus, overexpression of miR‐26a‐5p could be a novel therapy to improve CME‐induced myocardial damage.


  • Retracted

    RETRACTED: Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials

    by Ziliang Ye, Haili Lu, Qiang Su, Manyun Long, Lang Li

    Aims Whether a loading dose of atorvastatin (80mg) can reduce major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) remains controversial. Therefore, we performed this meta-analysis. Methods and results Randomized controlled trials (RCT) comparing a loading dose of atorvastatin to a control in patients with ACS who underwent PCI were identified through searches of medical literature databases. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the primary endpoint. Finally, 13 trials enrolling 22095 patients were included; of the 22095 patients, 11214 (50.7%) received loading doses of 80mg of atorvastatin. Compared with the control, atorvastatin significantly reduced MACE (RR: 0.66, 95% CI 0.54-0.80), myocardial infarction (MI; RR: 0.61, 95% CI 0.46-0.80), revascularization (RR: 0.76, 95% CI 0.69-0.83), and stroke (RR: 0.69, 95% CI 0.49-0.96). There was no difference in death or rehospitalization between the two groups. In the subgroup analysis, atorvastatin still significantly reduced MACE (RR: 0.57, 95% CI 0.39-0.85) and MI (RR: 0.61, 95% CI 0.42-0.89) within 30days. Furthermore, atorvastatin still remarkably reduced MACE (RR: 0.70, 95% CI 0.55-0.89), MI (RR: 0.58, 95% CI 0.36-0.95), and revascularization (RR: 0.76, 95% CI 0.69-0.84) after more than 30days. No significant differences were observed in death or stroke within 30days or after more than 30days. Conclusion Our meta-analysis supports the concept that a loading dose of atorvastatin markedly reduces cardiovascular events in patients with ACS.


  • Open Access

    miR-30e-5p Mitigates Hypoxia-Induced Apoptosis in Human Stem Cell-Derived Cardiomyocytes by Suppressing Bim

    by Binhai Mo, Xiaodan Wu, Xiantao Wang, Jian Xie, Ziliang Ye, Lang Li

    Coronary microembolization can cause slow or no reflow, which is one of the crucial reasons for reverse of clinical advantage from cardiac reperfusion therapy. miRNAs and apoptosis are dramatically involved in the occurrence and process of cardiovascular diseases. Fortunately, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have emerged as an appealing model for the evaluation of cardiovascular diseases. Therefore, our study was designed to explore the role of miR-30e-5p and apoptosis in a hypoxia-induced hiPSC-CM injury model. Our results showed that the expression levels of miR-30e-5p were overtly downregulated in a time-dependent manner under hypoxic conditions. Expression of miR-30e-5p was significantly downregulated after 24 hours of hypoxia, hypoxia treatment dramatically induced apoptosis. Calcium handling capability significantly decreased after 24 hours of hypoxia treatment. miR-30e-5p overexpression partially mitigated hypoxia-induced apoptosis and rescued hypoxia-induced calcium handling defects in hiPSC-CMs. The luciferase reporter assay showed that miR-30e-5p can directly target the 3'-UTR of Bim, which is an apoptosis activator and autophagy suppressor. The mRNA and protein of Bim remarkably increased after hypoxia treatment and reduced with miR-30e-5p overexpression. Moreover, downregulation of Bim mitigated hypoxia-induced apoptosis and activated autophagy. These results demonstrated that miR-30e-5p mitigated hypoxia-induced apoptosis in hiPSC-CMs at least in part via Bim suppression and subsequent autophagy activation. Our study suggested miR-30e-5p may act as a potential therapeutic target for coronary microembolization.


  • Open Access

    Baseline Serum Uric Acid Levels Are Associated with All-Cause Mortality in Acute Coronary Syndrome Patients after Percutaneous Coronary Intervention

    by Ziliang Ye, Haili Lu, Manyun Long, Lang Li

    Background. Whether serum uric acid (UA) is associated with all-cause mortality in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI) remains unclear. Methods. We performed a retrospective cohort study of 2296 patients with ACS. Curve-fitting and Cox proportional-hazard regression models with a hazard ratio (HR) and 95% confidence interval (CI) were used. Results. During a mean follow-up of 246.31 ± 49.16 days, 168 (7.32%) patients died from all causes. Patients were divided into two groups [the high-UA group (n=566) and the low-UA group (n=1730)] based on the serum UA threshold value (5.6 mg/dl) identified through curve fitting. Fifty-three (9.36%) patients died in the high-UA group, and 115 (6.65%) patients died in the low-UA group. The difference between groups was statistically significant (P=0.031). Univariate analysis showed that the risk of all-cause mortality in the high-UA group was significantly greater than that in the low-UA group (HR = 1.45, 95% CI: 1.03 to 2.04). This difference persisted after adjustment for baseline characteristics, medical history, and medication history (HR = 1.42, 95% CI: 1.05 to 1.87). Conclusions. Our study demonstrated that elevated serum UA (>5.6 mg/dl) is associated with all-cause mortality in ASC patients after PCI.


  • Open Access

    Reduced Left Ventricular Ejection Fraction Is a Risk Factor for In-Hospital Mortality in Patients after Percutaneous Coronary Intervention: A Hospital-Based Survey

    by Ziliang Ye, Haili Lu, Lang Li

    Background. To evaluate whether a reduced left ventricular ejection fraction (LVEF) is a risk factor in patients after percutaneous coronary intervention (PCI). Methods. A retrospective cohort study from February 2013 to January 2017 was performed, and 1600 patients were included (136 patients with EF Results. The mean age of patients with EF Conclusions. Reduced LVEF is a risk factor for in-hospital mortality in patients after PCI.